• Biogen published an AAIC 2026 medical research presentation outlining Phase 2 CELIA results for tau-targeting diranersen in early Alzheimer’s disease.
• Primary endpoint missed; the prespecified dose-response on CDR-SB at Week 76 was not met.
• Low-dose 60 mg Q24W showed a 0.54-point, 26% CDR-SB difference versus placebo at Week 76; cognitive measures favored treatment, including 50% on MMSE.
• Biomarkers favored diranersen, including tau PET and CSF total tau reductions; ARIA was not observed in CELIA.
• Program next steps include a long-term extension study, continued analyses, regulator engagement, and Phase 3 trial planning.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.